VWR Corporation (VWR) & Intersect ENT (XENT) Financial Contrast

Intersect ENT (NASDAQ: XENT) and VWR Corporation (NASDAQ:VWR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitabiliy, earnings, analyst recommendations, risk and institutional ownership.

Risk and Volatility

Intersect ENT has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Comparatively, VWR Corporation has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.

Profitability

This table compares Intersect ENT and VWR Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Intersect ENT -28.71% -20.49% -18.29%
VWR Corporation 3.25% 15.39% 4.61%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Intersect ENT and VWR Corporation, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intersect ENT 0 3 7 0 2.70
VWR Corporation 1 4 3 0 2.25

Intersect ENT currently has a consensus price target of $18.78, suggesting a potential downside of 28.87%. VWR Corporation has a consensus price target of $31.80, suggesting a potential downside of 3.58%. Given VWR Corporation’s higher probable upside, analysts clearly believe VWR Corporation is more favorable than Intersect ENT.

Earnings & Valuation

This table compares Intersect ENT and VWR Corporation’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Intersect ENT $82.49 million 9.21 -$23.42 million ($0.83) -31.81
VWR Corporation $4.55 billion 0.95 $480.40 million $1.12 29.45

VWR Corporation has higher revenue and earnings than Intersect ENT. Intersect ENT is trading at a lower price-to-earnings ratio than VWR Corporation, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

76.1% of Intersect ENT shares are held by institutional investors. 13.9% of Intersect ENT shares are held by company insiders. Comparatively, 35.5% of VWR Corporation shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

VWR Corporation beats Intersect ENT on 9 of the 13 factors compared between the two stocks.

About Intersect ENT

Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company’s commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.

About VWR Corporation

VWR Corporation is a provider of product and service solutions to laboratory and production customers. The Company offers a portfolio of branded and private label laboratory products, services and solutions to the life science, general research and applied markets. The Company operates in two segments: Americas and EMEA-APAC. The Americas segment consists of operations located principally in the United States and Canada, as well as in Puerto Rico, Mexico and select countries in Central and South America, including Costa Rica, Brazil, Argentina and Chile. As of December 31, 2016, the Americas segment included 67 facilities located in eight countries. As of December 31, 2016, the EMEA-APAC segment consisted of its operations located principally in Europe, as well as in certain Asia-Pacific countries, and included 110 facilities located in 26 countries. The Company’s portfolio includes chemicals, reagents, consumables, durable products and scientific equipment and instruments.

Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.